|  | Mean ± S.D. | Median | Range |
---|---|---|---|---|
Age (year) |  | 31.8 ± 7.0 | 31 | 18 – 44 |
Sex (male/female) | 15/5 | Â | Â | Â |
Body Weight (kg) |  | 67.0 ± 12.5 | 65.0 | 45.5 – 91.8 |
Body surface area (m2) |  | 1.8 ± 0.2 | 1.8 | 1.4 – 2.1 |
Body mass index (kg/m2) |  | 23.2 ± 3.3 | 23.1 | 15.5 – 28.8 |
Diagnosis | Â | Â | Â | Â |
  ALL | 17 |  |  |  |
  AML | 2 |  |  |  |
  ANKL | 1 |  |  |  |
Disease status at SCT | Â | Â | Â | Â |
  CR1 | 14 |  |  |  |
  CR2 | 1 |  |  |  |
  non CR | 4 |  |  |  |
  relapse 1 | 1 |  |  |  |
Donor | Â | Â | Â | Â |
  MRD | 6 |  |  |  |
  MUD | 7 |  |  |  |
  MMRD | 1 |  |  |  |
  MMUD | 6 |  |  |  |
Stem cell source | Â | Â | Â | Â |
  Bone marrow | 15 |  |  |  |
  Peripheral blood stem cells | 3 |  |  |  |
  Umbilical cord blood | 2 |  |  |  |
GVHD Prophylaxis | Â | Â | Â | Â |
  CSP + MTX | 9 |  |  |  |
  TAC + MTX | 11 |  |  |  |
Laboratory data | Â | Â | Â | Â |
  Alb (g/dL) |  | 4.0 ± 0.4 | 4.0 | 2.8 – 4.9 |
  T-pro (g/dL) |  | 6.0 ± 0.4 | 5.8 | 5.4 – 7.0 |
  BUN (mg/dL) |  | 10.3 ± 3.0 | 10.5 | 5.0 – 15.0 |
  Scr (mg/dL) |  | 0.6 ± 0.2 | 0.6 | 0.3 – 1.0 |
  T-bil (mg/dL) |  | 0.7 ± 0.3 | 0.7 | 0.4 – 1.7 |
  AST (IU/L) |  | 35.0 ± 31.4 | 21.0 | 9.0 – 125 |
  ALT (IU/L) |  | 45.6 ± 54.6 | 32.0 | 5.0 – 251 |